Anika Growth Driven by Arthrosurface and Parcus Acquisitions

Anika Therapeutics' logo

Anika Therapeutics reported 3Q20 orthopedic revenue of USD $30.2 million, +7.2% vs. 3Q19. The company’s joint replacement and sports medicine businesses rebounded with the return of elective procedures. Anika’s largely office-based orthobiologics business is running at 75% of historical levels and is also impacted by purchasing patterns from...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us